Navigation Links
Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls

re is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company's website: www.shire.com.

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD) and SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire's ability to benefit from its acquisition of New River Pharmaceuticals Inc.; and other risks and uncertainties detailed from time to time in
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
7. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
8. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
9. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
Post Your Comments:
(Date:12/1/2008)...O, Dec. 1 TargeGen has announced t...from a multi-center, US-based clinical,trial of T... been scheduled at,the 2008 American Society of H... presentation are as follows:, Title: ...vailable, JAK2-Selective I...
(Date:12/1/2008)...stinence is still the best policy , , ROCH...new study from Mayo Clinic finds the use of the dr...holic hepatitis, an acute inflammation of the live...results of the study are published in the December...urnal.org/ ). , , VIDEO ALERT: Additional ...
(Date:12/1/2008)...O, Dec. 1 Vical Incorpor... of a $1.0 million milestone payment from Merck &a...of a Phase I clinical trial of an investigational ...accine is based on Vical,s DNA gene delivery techn...iptase (hTERT). hTERT is the subject of separate l...
(Date:11/27/2008)...y finds the majority of acute lymphoblastic leukem... at the time of diagnosis , , MEMPHIS, Tenn...t St. Jude Children,s Research Hospital have ident...lls of children with acute lymphoblastic leukemia ...hway to designing treatments for ALL relapse in ch...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Progress toward new storage media 8631 1Progress toward new storage media 8631 2Anadys Pharmaceuticals to Present at Bio Investor Forum 27824 1Anadys Pharmaceuticals to Present at Bio Investor Forum 27824 2MU researchers advance health communication for at risk populations 27821 1MU researchers advance health communication for at risk populations 27821 2Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 1Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 2Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 3Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 4
... Since the level of blood oxygenation can be an es... of hemoglobin levels in the clinical setting is o...o incorporate sophisticated technology into easily...several manufacturers offer prompt assessment of h..., Calif., says that its HemoCue Hemoglobin Test Sy...
... Although it may still seem radically innovative i...ated production in the manufacturing sector had be..., for example, automated lines fabricate sub-assem...an oversight. The result has been vastly improved ...ive returns in profit and productivity. These days...
Other Medicine Technology:Hemoglobin Testing at the Point of Care 2Hemoglobin Testing at the Point of Care 3Lab Automation Networks Proliferating 2Lab Automation Networks Proliferating 3Lab Automation Networks Proliferating 4
(Date:12/2/2008)...c. 2 Aduromed Industries...ider of medical waste treatment,systems, today an...n November,24, 2008 to protect the Company,s prop...rized MedClean Systems that provide a turnkey solu...tion and volume reduction. , The patent app...
(Date:12/2/2008)... Dec. 2 Genoptix, Inc. (...s provider, today announced the Company,s particip...onference scheduled to take place at the Westin Ne...08. , , Sam Riccitelli, COO and executive...anel discussion at the conference on Wednesday, De...
(Date:12/2/2008)...f., Dec. 2 In response to the comm..., Frequent Respiratory Infections, and the Vitamin... by 16 well known supplement experts, Nordic Natur...s pose no threat or compromise to consumers and ac...at are low in natural Vitamin A. According to Kari...
(Date:12/2/2008)...alif., Dec. 2 Internationally reco...as an invited speaker for this,year,s annual meet..., (Photo: http://www.newscom.com/cgi-bin/p...,Why is minimally invasive (or ,Goldilocks,) anest...tled ,PK 101, minimally invasive,anesthesia for m...
Breaking Medicine News(10 mins):Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 2Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 3Health News:Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2
...ment has repeated its plea to doctors over prescri...could save ?85 millions in the coming year if GPs/... Primary Care Trusts (PCTs) can prescribe generic ...mvastatin, which are two of five ‘statin’ drugs th...
...exercise by doing household chores like dusting, m...east cancer, suggests a new study.// The research... women from nine European countries and found that... cancer protective than playing sport, reported th...
...s at the National Institutes of Health have discov...steogenesis //Imperfecta--a disorder that weakens ...lts from a genetic defect in a protein involved in...ted gene contains the information for cartilage as...
... your high blood pressure might just be your infla...dence suggests that inflammation, a part of the im...r, Alzheimer’s and diabetes, may also help transla...ressure. “There is a concept that hypertension is...
Other Medicine News:Health News:Researchers Discovered the Gene Responsible for Brittle Bone Disease 2Health News:Researchers Discovered the Gene Responsible for Brittle Bone Disease 3Health News:Inflammatory Genes Linked to Salt-Sensitive Hypertension 2Health News:Inflammatory Genes Linked to Salt-Sensitive Hypertension 3
The Medtronic StableMapr catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing associated
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available.
...heter is specifically designed for use with our CA...able NAVI-STAR catheter houses a Biosense Webster ..., exact location points from within the heart whil...rmation. The NAVI-STAR electro-anatomical navigati...
For Tricuspid Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters for mapping in the atrium. The HALO XP 20-pole deflectable catheter is designed for simple placement and
Medicine Products: